DSM Biomedical and Svelte Medical Systems, Inc. Execute License and Supply Agreement for DSM’s Proprietary Amino Acid Based–Drug Carrier for Svelte’s New All-in-One Drug-Eluting Stent System

BERKELEY, Calif.--(BUSINESS WIRE)--DSM, a global leader in biomedical materials, and Svelte® Medical Systems, Inc., a privately held company developing next generation endovascular therapies, today announced they have entered into a license and supply agreement granting Svelte the right to use DSM’s proprietary bioerodible amino acid based drug carrier in the design of a non-thrombogenic, non-inflammatory drug-eluting stent.